Pharmacokinetic and Pharmacodynamic Processes

Case Study: Patient CB has a history of strokes. The patient has been diagnosed with type 2 diabetes, hypertension, and hyperlipidemia. Drugs currently prescribed include the following:

• Glipizide 10 mg po daily

• HCTZ 25 mg daily

• Atenolol 25 mg po daily

• Hydralazine 25 mg qid

• Simvastatin 80 mg daily

• Verapamil 180 mg CD daily

Write a 2- to 3-page paper that addresses the following:

• select one the following factors: genetics, gender, ethnicity, age, or behavior factors.

• Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the above case study.

• Describe how changes in the processes might impact the patient’s recommended drug therapy. Be specific and provide examples.

• Explain how you might improve the patient’s drug therapy plan and explain why you would make these recommended improvements. If possible please use one of the follwing resources.

Some references: Reference:

ACC/ACHA Guideline on the Management of Blood Cholesterol

Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

Guideline on the Primary Prevention of Cardiovascular Disease

Guideline for the Management of Patients With Atrial Fibrillation

Guideline for the Management of Heart Failure

Strategies to Enhance Application of Clinical Practice Guidelines in Patients With Cardiovascular Disease and Comorbid Conditions

Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women

OTHER resources: Rosenthal, L. D., & Burchum, J. R. (2018). Lehne’s pharmacotherapeutics for advanced practice providers. St. Louis, MO: Elsevier.

• Chapter 34, “Review of Hemodynamics” (pp. 335–340)

• Chapter 35, “Diuretics” (pp. 341–349)

• Chapter 36, “Drugs Acting on the Renin-Angiotensin-Aldosterone System” (pp. 351–362)

• Chapter 37, “Calcium Channel Blockers” (pp. 363–369)

• Chapter 38, “Vasodilators” (pp. 371–373)

• Chapter 39, “Drugs for Hypertension” (pp. 375–388)

• Chapter 40, “Drugs for Heart Failure” (pp. 389–402)

• Chapter 41, “Antidysrhythmic Drugs” (pp. 403–418)

• Chapter 42, “Prophylaxis of Atherosclerotic Cardiovascular Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels” (pp. 419–439)

• Chapter 43, “Drugs for Angina Pectoris” (pp. 441–450)

• Chapter 44, “Anticoagulant and Antiplatelet Drugs” (pp. 451–472)

Place this order or similar order and get an amazing discount. USE Discount code “GET20” for 20% discount